{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:23:58Z","timestamp":1773465838562,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Untreated hemophilia A patients may experience recurrent bleeding events leading to debilitating joint damages. While RCT and pharmacokinetic data support the value of Kovaltry [an unmodified full-length recombinant factor VIII (FVIII) product], real world evidence in children is lacking. This report describes a descriptive and multivariate analysis of the effectiveness of Kovaltry in children with hemophilia A in the real-world setting, using data from medical chart abstraction and cross-sectional surveys of physicians, patients, and caregivers.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Male patients aged &lt;\u200918\u00a0years with moderate or severe hemophilia A, residing in five European countries and treated with FVIII were studied. The co-primary endpoints were the annualized bleeding rate (ABR) and the annual FVIII utilization rate. Twenty nine patients treated with Kovaltry were included, of whom 93% had severe disease and 75% were on continuous prophylactic treatment. The mean ABR was 2.66\u2009\u00b1\u20092.06, with rates decreasing with age. The children received on average 2.45 infusions per week, consistent across age groups (median 3; range 1\u20133). There were no reports of inhibitor development or adverse events in the study (AEs), and all patients were satisfied or very satisfied with the treatment. An exploratory multivariate analysis suggests no significant difference in ABR or units utilized between Kovaltry and some extended half life products in children with severe hemophilia A, though characteristics of these patient cohorts were markedly different.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This analysis demonstrates the effectiveness and safety of Kovaltry in a pan-European pediatric population with severe hemophilia A.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01676-w","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T10:03:05Z","timestamp":1610704985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a nested cohort analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Jamie","family":"O\u2019Hara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9094-2437","authenticated-orcid":false,"given":"Ceri","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Francisco","family":"Cabre Marquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"issue":"10040","key":"1676_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","volume":"388","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016;388(10040):187\u201397.","journal-title":"Lancet"},{"issue":"4","key":"1676_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I","volume":"59","author":"JM Soucie","year":"1998","unstructured":"Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The hemophilia surveillance system project investigators. Am J Hematol. 1998;59(4):288\u201394.","journal-title":"Am J Hematol"},{"key":"1676_CR3","unstructured":"Data & Statistics on Hemophilia. Center for Disease Control and Prevention. Page Last reviewed: 21 June, 2019. https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/data.html. Accessed 19 Mar 2020."},{"key":"1676_CR4","unstructured":"National Hemophilia Foundation. Last updated: 21 Jun 2019. https:\/\/www.hemophilia.org\/About-Us\/Fast-Facts. Accessed 19 Mar 2020."},{"key":"1676_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1538-7836.2006.01776.x","volume":"4","author":"C Mejia-Carvajal","year":"2006","unstructured":"Mejia-Carvajal C, Czapek EE, Valentino LA. Life expectancy in hemophilia outcome. J Thromb Haemost. 2006;4:507\u20139.","journal-title":"J Thromb Haemost"},{"key":"1676_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/blood-2006-10-050435","volume":"110","author":"SC Darby","year":"2007","unstructured":"Darby SC, Kan SW, Spooner RJ, Giangrande PLF, Hill FGH, Hay CRM, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110:815\u201325.","journal-title":"Blood"},{"key":"1676_CR7","unstructured":"World Federation of Hemophilia. Frequently asked questions about hemophilia. 2012. http:\/\/www.wfh.org\/en\/page.aspx?pid=637#Life_expectancy. Cited 31 Jul 2015."},{"key":"1676_CR8","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1111\/j.1538-7836.2010.03962.x","volume":"8","author":"LA Valentino","year":"2010","unstructured":"Valentino LA. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost. 2010;8:1895\u2013902.","journal-title":"J Thromb Haemost"},{"key":"1676_CR9","unstructured":"World Hemophilia Federation. https:\/\/www1.wfh.org\/publications\/files\/pdf-1472.pdf."},{"key":"1676_CR10","unstructured":"World Federation of Hemophilia: Report on the Annual Global Survey 2015. 2015. Accessed 19 Mar 2020."},{"key":"1676_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/pbc.24856","volume":"61","author":"K Lindvall","year":"2014","unstructured":"Lindvall K, von Mackensen S, Elmst\u00e5hl S, Khair K, Stain AM, Ljung R, et al. Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. Pediatr Blood Cancer. 2014;61:706\u201311.","journal-title":"Pediatr Blood Cancer"},{"key":"1676_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/hae.12379","volume":"20","author":"M DeKoven","year":"2014","unstructured":"DeKoven M, Karkare S, Kelley LA, Cooper DL, Pharm H, Powers J, et al. Understanding the experience of caring for children with haemophilia: cross-sectional study of caregivers in the United States. Haemophilia. 2014;20:541\u20139.","journal-title":"Haemophilia"},{"key":"1676_CR13","unstructured":"Role of new prolonged half-life clotting factors in hemophilia. National Hemophilia Foundation. https:\/\/www.hemophilia.org\/sites\/default\/files\/document\/files\/PHLBrochure.pdf. Accessed 19 Mar 2020."},{"key":"1676_CR14","unstructured":"ELOCTA (efmoroctocog alfa recombinant human coagulation factor VIII, Fc fusion protein). https:\/\/elocta.com\/. Accessed 19 Mar 2020."},{"key":"1676_CR15","unstructured":"ADYNOVI 250 IU\/5 ml powder and solvent for solution for injection. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adynovi-epar-product-information_en.pdf. Accessed 19 Dec 2020."},{"key":"1676_CR16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/DDDT.S188171","volume":"13","author":"JM Teare","year":"2019","unstructured":"Teare JM, Kates DS, Shah A, Garger S. Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81\u20138973 compared with other full-length rFVIII products. Drug Des Devel Ther. 2019;13:941\u20138.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"1676_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/hae.12866","volume":"22","author":"R Ljung","year":"2016","unstructured":"Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D, investigators of the LEOPOLD Kids Trial, et al. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia. 2016;22(3):354\u201360.","journal-title":"Haemophilia"},{"issue":"5","key":"1676_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/hae.12952","volume":"22","author":"K Saxena","year":"2016","unstructured":"Saxena K, Lalezari S, Oldenburg J, Tseneklidou-Stoeter D, Beckmann H, Yoon M, et al. Efficacy and safety of BAY 81\u20138973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia. 2016;22(5):706\u201312.","journal-title":"Haemophilia"},{"issue":"3","key":"1676_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/jth.12828","volume":"13","author":"K Kavakli","year":"2015","unstructured":"Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M, LEOPOLD II Study Investigators. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13(3):360\u20139.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"1676_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13023-017-0660-y","volume":"12","author":"J O\u2019Hara","year":"2017","unstructured":"O\u2019Hara J, Hughes D, Camp C, Burke T, Carroll L, Garcia Diego DA. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106.","journal-title":"Orphanet J Rare Dis."},{"key":"1676_CR21","unstructured":"O'Hara J, Khair K, McLaughlin P, O'Mahony B, Laffan M, Pasi J et al. \u201cProblem Joint\u201d\u2014a more patient relevant definition for joint morbidity in haemophilia. Poster Presented at the European Association for Hemophilia and Allied Disorders (EAHAD): 6\u20138 February, 2019, Czech Republic."},{"issue":"3","key":"1676_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/bjc.2013.725","volume":"110","author":"CM Booth","year":"2014","unstructured":"Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551\u20135.","journal-title":"Br J Cancer"},{"key":"1676_CR23","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence\u2014what is it and what can it tell us? N Engl J Med. 2016;375:2293\u20137.","journal-title":"N Engl J Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01676-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01676-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01676-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T10:05:59Z","timestamp":1610705159000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01676-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1676"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01676-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"11 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The CHESS protocol was approved by the ethics committee of the University of Chester, UK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J O\u2019Hara and T Burke have received consulting fees from Bayer as well as several other pharmaceutical companies. J Cabre Marquez\u00a0and C Hirst are current employees of Bayer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}